Synapse - First-in-human imaging with (89)Zr-Df-IAB2M Anti-PSMA minibody in patients with metastatic prostate cancer: Pharmacokinetics, biodistribution, dosimetry, and lesion uptake

First-in-human imaging with (89)Zr-Df-IAB2M Anti-PSMA minibody in patients with metastatic prostate cancer: Pharmacokinetics, biodistribution, dosimetry, and lesion uptake Journal Article

Authors:	Pandit-Taskar, N.; O'Donoghue, J. A.; Ruan, S.; Lyashchenko, S. K.; Carrasquillo, J. A.; Heller, G.; Martinez, D. F.; Cheal, S. M.; Lewis, J. S.; Fleisher, M.; Keppler, J. S.; Reiter, R. E.; Wu, A. M.; Weber, W. A.; Scher, H. I.; Larson, S. M.; Morris, M. J.
Article Title:	First-in-human imaging with (89)Zr-Df-IAB2M Anti-PSMA minibody in patients with metastatic prostate cancer: Pharmacokinetics, biodistribution, dosimetry, and lesion uptake
Abstract:	We conducted a phase I dose-escalation study with 89Zr-desferrioxamine-IAB2M (89Zr-IAB2M), an anti-prostate-specific membrane antigen minibody, in patients with metastatic prostate cancer. Methods: Patients received 185 MBq (5 mCi) of 89Zr-IAB2M and Df-IAB2M at total mass doses of 10 (n = 6), 20 (n = 6), and 50 mg (n = 6). Wholebody and serum clearance, normal-organ and lesion uptake, and radiation absorbed dose were estimated, and the effect of mass escalation was analyzed. Results: Eighteen patients were injected and scanned without side effects. Whole-body clearance was monoexponential, with a median biologic half-life of 215 h, whereas serum clearance showed biexponential kinetics, with a median biologic half-life of 3.7 (12.3%/L) and 33.8 h (17.9%/L). The radiation absorbed dose estimates were 1.67, 1.36, and 0.32 mGy/MBq to liver, kidney, and marrow, respectively, with an effective dose of 0.41mSv/MBq (1.5 rem/mCi). Both skeletal and nodal lesions were detected with 89Zr-IAB2M, most visualized by 48-h imaging. Conclusion: 89Zr-IAB2M is safe and demonstrates favorable biodistribution and kinetics for targeting metastatic prostate cancer. Imaging with 10 mg of minibody mass provides optimal biodistribution, and imaging at 48 h after injection provides good lesion visualization. Assessment of lesion targeting is being studied in detail in an expansion cohort. COPYRIGHT © 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
Keywords:	dosimetry; psma; minibody; 89zr- iab2m; prostate cancer imaging
Journal Title:	Journal of Nuclear Medicine
Volume:	57
Issue:	12
ISSN:	0161-5505
Publisher:	Society of Nuclear Medicine
Date Published:	2016-12-01
Start Page:	1858
End Page:	1864
Language:	English
DOI:	10.2967/jnumed.116.176206
PROVIDER:	scopus
PUBMED:	27516450
PMCID:	PMC5450345
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85001075179&doi=10.2967%2fjnumed.116.176206&partnerID=40&md5=42dc54f9dace08685a43e71f37047aef
Notes:	Article -- Export Date: 3 January 2017 -- Source: Scopus